MedTrace Logo

C-Type Natriuretic Peptide and Achondroplasia

NCT01541306 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 91

Last updated 2015-04-14

No results posted yet for this study

Summary

Achondroplasia and hypochondroplasia are the most common forms of dwarfism. Recent studies have shown that a small hormone called C-type natriuretic peptide (CNP) is an important regulator of linear growth. The investigators believe that genetic abnormality that causes achondroplasia and hypochondroplasia also disrupts CNP signaling, which may contribute to the growth problem. The investigators propose to look at levels of this and other closely related hormones in children and adults with achondroplasia or hypochondroplasia to see if they are different from levels in healthy people. The investigators hypothesis is that CNP levels are elevated in children with achondroplasia or hypochondroplasia, compared the healthy population. Another hypothesis is that CNP levels are not elevated in adults with achondroplasia or hypochondroplasia, since adults have no growth-plate cartilage. By studying the potential role of the CNP system in achondroplasia and hypochondroplasia, not only will the investigators provide further insight into the pathophysiology of these common syndromes, the investigators will also provide greater insight into the regulation of normal linear growth.

Conditions

Sponsors & Collaborators

  • Alfred I. duPont Hospital for Children

    collaborator OTHER

  • University of Otago

    collaborator OTHER

  • Nemours Children's Clinic

    lead OTHER

Principal Investigators

  • Robert Olney, MD · Nemours Children's Clinic

  • Michael Bober, MD, PhD · Alfred I. duPont Hospital for Children

Eligibility

Min Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01541306 on ClinicalTrials.gov